159 related articles for article (PubMed ID: 3874596)
1. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency.
Klein RJ; Friedman-Kien AE
Antimicrob Agents Chemother; 1985 May; 27(5):763-8. PubMed ID: 3874596
[TBL] [Abstract][Full Text] [Related]
2. Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.
Klein RJ; DeStefano E; Brady E; Friedman-Kien AE
Antimicrob Agents Chemother; 1979 Sep; 16(3):266-70. PubMed ID: 507784
[TBL] [Abstract][Full Text] [Related]
3. Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds.
Klein RJ
Am J Med; 1982 Jul; 73(1A):138-42. PubMed ID: 6285703
[TBL] [Abstract][Full Text] [Related]
4. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice.
Fraser-Smith EB; Eppstein DA; Marsh YV; Matthews TR
Antimicrob Agents Chemother; 1984 Dec; 26(6):937-8. PubMed ID: 6335382
[TBL] [Abstract][Full Text] [Related]
6. Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs.
Park NH; Pavan-Langston D; McLean SL; Lass JH
Arch Dermatol; 1980 Jun; 116(6):672-5. PubMed ID: 7377804
[TBL] [Abstract][Full Text] [Related]
7. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.
Klein RJ; Friedman-Kien AE; DeStefano E
Antimicrob Agents Chemother; 1979 May; 15(5):723-9. PubMed ID: 230784
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
[TBL] [Abstract][Full Text] [Related]
9. Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.
Thackray AM; Field HJ
Antimicrob Agents Chemother; 1998 Jul; 42(7):1555-62. PubMed ID: 9660982
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.
Sutton D; Boyd MR
Antimicrob Agents Chemother; 1993 Apr; 37(4):642-5. PubMed ID: 8388195
[TBL] [Abstract][Full Text] [Related]
11. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.
Boyd MR; Bacon TH; Sutton D
Antimicrob Agents Chemother; 1988 Mar; 32(3):358-63. PubMed ID: 3364954
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.
Fraser-Smith EB; Eppstein DA; Marsh YV; Matthews TR
Antimicrob Agents Chemother; 1984 May; 25(5):563-5. PubMed ID: 6610387
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs.
Fraser-Smith EB; Smee DF; Matthews TR
Antimicrob Agents Chemother; 1983 Dec; 24(6):883-7. PubMed ID: 6607031
[TBL] [Abstract][Full Text] [Related]
14. Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides.
Smee DF; Campbell NL; Matthews TR
Antiviral Res; 1985 Oct; 5(5):259-67. PubMed ID: 2998275
[TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with gamma interferon against herpes simplex virus type 2 in mice.
Fraser-Smith EB; Eppstein DA; Marsh YV; Matthews TR
Antiviral Res; 1985 Jun; 5(3):137-44. PubMed ID: 2992368
[TBL] [Abstract][Full Text] [Related]
16. Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.
Klein RJ; DeStefano E; Friedman-Kien AE; Brady E
Antimicrob Agents Chemother; 1981 May; 19(5):937-9. PubMed ID: 6271054
[TBL] [Abstract][Full Text] [Related]
17. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice.
Docherty JJ; Smith JS; Fu MM; Stoner T; Booth T
Antiviral Res; 2004 Jan; 61(1):19-26. PubMed ID: 14670590
[TBL] [Abstract][Full Text] [Related]
18. Effect of a thymidine kinase inhibitor (L-653,180) on antiviral treatment of experimental herpes simplex virus infection in mice.
Klein RJ; Czelusniak SM
Antiviral Res; 1990; 14(4-5):207-14. PubMed ID: 2088206
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 2'-nor-2'-deoxyguanosine treatment for orofacial herpes simplex virus type 1 skin infections in mice.
Davies ME; Bondi JV; Field AK
Antimicrob Agents Chemother; 1984 Feb; 25(2):238-41. PubMed ID: 6608919
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment of maintenance of latent herpes simplex virus infection in mice.
Field HJ; De Clercq E
J Gen Virol; 1981 Oct; 56(Pt 2):259-65. PubMed ID: 6273499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
